The future of treatment in systemic sclerosis: can we design better trials?
Author:
- Janet E PopeJPJanet E Pope
- 1 March 2020
- journal article
- Published by Elsevier in The Lancet Rheumatology
- Vol. 2 (3) , e185-e194
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator‐Initiated, Multicenter, Double‐Blind, Randomized, Placebo‐Controlled TrialArthritis & Rheumatology, 2019
- Myeloablative Autologous Stem-Cell Transplantation for Severe SclerodermaNew England Journal of Medicine, 2018
- Editorial: Bench to Bedside—and Back Again: Finding the Goldilocks Zone Within the Scleroderma UniverseArthritis & Rheumatology, 2017
- Belimumab for the Treatment of Early Diffuse Systemic SclerosisArthritis & Rheumatology, 2017
- Systemic sclerosisThe Lancet, 2017
- Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)Annals of the Rheumatic Diseases, 2017
- Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trialThe Lancet, 2016
- Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)Current Rheumatology Reports, 2016
- Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic SclerosisJAMA, 2014
- Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trialThe Lancet, 2011